New cancer database will share failures, not just successes |
Only 1% of cancer research data meets standards that allow other scientists to meaningfully use it. The rest sits in institutional silos, inaccessible or incompatible with outside analysis.
A new initiative aims to change that. The Cancer Research Institute has launched the CRI Discovery Engine, an open-access database designed specifically for immunotherapy research. The platform will standardize how data is collected and shared, making it usable by researchers worldwide. The data will also be accessible to AI tools that can spot patterns humans might miss.
Importantly, it will also include data on failed treatments. Negative results rarely get published, yet understanding why a therapy didn’t work can be as valuable as knowing why one did. The first phase of the database will focus on melanoma and colorectal cancer.
“By building a shared, high-resolution understanding of how the human immune system responds to interventions over time, we’re unlocking a new era of discovery,” principal investigator Ansuman Satpathy, MD, PhD, told Medical News Today.
To discover how this collaborative approach could reshape cancer treatment development, jump to “AI-ready open database aims to accelerate cancer immunotherapy research.”
Also making headlines this week:
| |
